Altimmune Inc (ALT) concluded trading on Wednesday at a closing price of $7.07, with 4.11 million shares of worth about $29.06 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 195.82% during that period and on May 01, 2024 the price saw a gain of about 7.94%. Currently the company’s common shares owned by public are about 70.68M shares, out of which, 70.17M shares are available for trading.
Stock saw a price change of -0.14% in past 5 days and over the past one month there was a price change of -24.43%. Year-to-date (YTD), ALT shares are showing a performance of -37.16% which increased to 43.70% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.09 but also hit the highest price of $14.84 during that period. The average intraday trading volume for Altimmune Inc shares is 4.67 million. The stock is currently trading -8.26% below its 20-day simple moving average (SMA20), while that difference is down -22.86% for SMA50 and it goes to 17.09% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Altimmune Inc (NASDAQ: ALT) currently have 70.68M outstanding shares and institutions hold larger chunk of about 62.73% of that.
The stock has a current market capitalization of $501.26M and its 3Y-monthly beta is at 0.20. It has posted earnings per share of -$1.64 in the same period. It has Quick Ratio of 17.25 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALT, volatility over the week remained 8.73% while standing at 7.91% over the month.
Stock’s fiscal year EPS is expected to drop by -1.29% while it is estimated to decrease by -9.83% in next year.
Coverage by Goldman stated Altimmune Inc (ALT) stock as a Neutral in their note to investors on January 24, 2024, suggesting a price target of $13 for the stock. On March 22, 2023, Goldman Downgrade their recommendations, while on December 01, 2022, Goldman Initiated their ratings for the stock with a price target of $20. Stock get a Buy rating from Jefferies on December 29, 2021.
